Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 12:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Anti-TNF Clear all

Conditions: Melanoma, Head and Neck Squamous Cell Carcinoma
Interventions: TILT-123, Avelumab; Biological · Drug
Lead sponsor: TILT Biotherapeutics Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Pediatric Crohn's Disease
Interventions: Methotrexate, Sugar pill (placebo); Drug · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: Up to 20 Years
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 32
States / cities: Birmingham, Alabama • Alto, California • New Haven, Connecticut + 27 more

Conditions: Crohn's Disease
Interventions: adalimumab, placebo; Biological
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 7
States / cities: Atlanta, Georgia • Chicago, Illinois • Chevy Chase, Maryland + 4 more

Conditions: Rheumatoid Arthritis
Interventions: Leflunomide, Methotrexate, Ocrelizumab, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 836 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 144
States / cities: Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 116 more

Conditions: Juvenile Idiopathic Arthritis Associated Uveitis, Uveitis, Anterior
Interventions: Adalimumab/Biosimilar; Biological
Lead sponsor: Nisha Acharya; Other
Eligibility: 2 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 9
States / cities: Los Angeles, California • Sacramento, California • San Francisco, California + 6 more

Conditions: Advanced Solid Tumor, Cutaneous T-cell Lymphoma (CTCL)
Interventions: SIM1811-03; Drug
Lead sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 6
States / cities: Detroit, Michigan • New York, New York • Huntersville, North Carolina + 2 more

Conditions: Rheumatoid Arthritis
Interventions: MabThera/Rituxan, Methotrexate, Placebo; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2012
U.S. locations: 67
States / cities: Birmingham, Alabama • Mesa, Arizona • Paradise Valley, Arizona + 54 more

Conditions: Crohn's Disease
Interventions: Double-blind (DB) adalimumab placebo, DB adalimumab 40 mg eow, DB adalimumab 40 mg ew, OL adalimumab 40 mg; Biological
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 43
States / cities: Berkeley, California • Long Beach, California • San Diego, California + 36 more

Conditions: Juvenile Idiopathic Arthritis
Interventions: Withdrawal of anti-TNF therapy; Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 4 Years to 20 Years
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 16
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 13 more

Conditions: Rheumatoid Arthritis
Interventions: Certolizumab Pegol (CZP), Arthroscopic synovial tissue biopsy; Drug · Procedure
Lead sponsor: Nathan Wei, MD, FACP, FACR:; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Frederick, Maryland

Conditions: Asthma
Interventions: Etanercept; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 13
States / cities: Birmingham, Alabama • Denver, Colorado • Sarasota, Florida + 10 more

Conditions: Inflammatory Bowel Disease, Crohn Disease, Ulcerative Colitis
Interventions: 23-valent polysaccharide pneumococcal vaccine (Pneumovax TM); Biological
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: HIV, Inflammation
Interventions: Assess Safety, Effect of drug on viral load, Effect of drug on T-cell count, Effect of drug on inflammatory biomarkers; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Rheumatoid Arthritis
Interventions: Abatacept, Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD), Anti-Tumor Necrosing Factor (TNF) Therapy; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 114
States / cities: Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 111 more

Conditions: Berylliosis, Beryllium Disease
Interventions: Infliximab, Placebo; Drug · Other
Lead sponsor: Maier, Lisa, M.D.; Individual
Eligibility: 18 Years to 80 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Axial Spondyloarthritis
Interventions: Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg, Golimumab 50 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 347 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 11
States / cities: Peoria, Arizona • St. Petersburg, Florida • Tampa, Florida + 8 more

Conditions: Spondylitis, Ankylosing
Interventions: golimumab, Golimumab (CNTO 148); placebo; Biological
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 11
States / cities: Paradise Valley, Arizona • Los Angeles, California • San Francisco, California + 8 more

Conditions: Juvenile Idiopathic Arthritis
Interventions: CNTO 148 (Golimumab), Placebo, Methotrexate; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • Augusta, Georgia + 4 more

Conditions: Ulcerative Colitis
Interventions: AVX 470, Placebo; Drug
Lead sponsor: Avaxia Biologics, Incorporated; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 9
States / cities: Anaheim, California • Lakewood, Colorado • Winter Park, Florida + 6 more

Conditions: Rheumatoid Arthritis
Interventions: LY2439821, Placebo; Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 37
States / cities: Peoria, Arizona • La Mesa, California • Palm Desert, California + 34 more

Conditions: Crohn's Disease
Interventions: CPSI-2364 or placebo; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions: anti-thymocyte globulin, etanercept; Biological
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 4
States / cities: Bellingham, Washington • Port Angeles, Washington • Seattle, Washington

Conditions: Ulcerative Colitis
Interventions: Adalimumab, Placebo; Biological
Lead sponsor: AbbVie; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 16
States / cities: Los Angeles, California • San Francisco, California • Orlando, Florida + 11 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Allogeneic Pancreatic Islet Cells, Deoxyspergualin, Antithymocyte globulin, Daclizumab or basiliximab, Sirolimus, Tacrolimus, Etanercept; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 3
States / cities: San Francisco, California • Chicago, Illinois • Minneapolis, Minnesota

Search by objective public record fields.

Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1

Low Dose Oral Methotrexate in Pediatric Crohn's Disease Patients Initiating Anti-Tumor Necrosis Factor (Anti-TNF) Therapy

Effects of Adalimumab on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon

A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)

Adalimumab Dose Adjustment for Pediatric Uveitis Treatment Trial

A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma

A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha Therapy

Remission in Subjects With Crohn's Disease, 1 Year Phase

Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA

Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab Pegol (Cimzia)

Study Evaluating Etanercept in Moderate to Severe Asthma

Pneumococcal Vaccination in Patients With Inflammatory Bowel Disease

CC-11050 in Human Immunodeficiency Virus-1-Infected Adults With Suppressed Plasma Viremia on Antiretroviral Therapy (APHRODITE)

Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy

Beryllium Infliximab Study: Clinical Interventional Trial

A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis

A Study of the Safety and Efficacy of Golimumab in Subjects With Active Ankylosing Spondylitis

A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)

Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis

A Study in Patients With Rheumatoid Arthritis

Single Ascending Dose Study of Oral CPSI-2364 (Semapimod)

Anti-Thymocyte Globulin and Etanercept in Treating Patients With Myelodysplastic Syndromes

Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis

Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes